Background Tranexamic acid (TXA) reduces surgical bleeding and reduces death from
bleeding after trauma and childbirth. However, its effects on thrombotic events and seizures …

Tranexamic acid, a synthetic derivative of the amino acid lysine, is an antifibrinolytic agent
that acts by binding to plasminogen and blocking the interaction of plasmin (ogen) with …

Background Tranexamic acid reduces the risk of bleeding among patients undergoing
cardiac surgery, but it is unclear whether this leads to improved outcomes. Furthermore …

Importance Traumatic brain injury (TBI) is the leading cause of death and disability due to
trauma. Early administration of tranexamic acid may benefit patients with TBI. Objective To …

Importance Tranexamic acid is recommended for reducing blood loss and transfusion in
cardiac surgery. However, it remains unknown whether a high dose of tranexamic acid …

Cardiopulmonary bypass (CPB) provides a bloodless field for cardiac surgery. It
incorporates an extracorporeal circuit to provide physiological support in which venous …

Blood loss and subsequent transfusions are associated with major morbidity and mortality.
The use of antifibrinolytics can reduce blood loss in cardiac surgery, trauma, orthopedic …

Experience with tranexamic acid, an indirect fibrinolytic inhibitor, started as soon as it was
released from Shosuke Okamoto's lab in the early 1960s. It was first prescribed to females …

Antifibrinolytic drugs are routinely used worldwide to reduce the bleeding that results from a
wide range of hemorrhagic conditions. The most commonly used antifibrinolytic drug …

There has been an explosion of interest in the ability of tranexamic acid to reduce morbidity
and mortality in surgical and traumatic bleeding. Tranexamic acid has been shown to reduce …